EXEL Stock Overview
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
No risks detected for EXEL from our risk checks.
Exelixis, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$16.94|
|52 Week High||US$23.40|
|52 Week Low||US$14.87|
|1 Month Change||3.67%|
|3 Month Change||-7.08%|
|1 Year Change||-0.70%|
|3 Year Change||1.86%|
|5 Year Change||-39.76%|
|Change since IPO||11.54%|
Recent News & Updates
|EXEL||US Biotechs||US Market|
Return vs Industry: EXEL exceeded the US Biotechs industry which returned -14.4% over the past year.
Return vs Market: EXEL exceeded the US Market which returned -18.5% over the past year.
|EXEL Average Weekly Movement||4.3%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: EXEL is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: EXEL's weekly volatility (4%) has been stable over the past year.
About the Company
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Exelixis, Inc. Fundamentals Summary
|EXEL fundamental statistics|
Is EXEL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EXEL income statement (TTM)|
|Cost of Revenue||US$54.91m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.95|
|Net Profit Margin||18.78%|
How did EXEL perform over the long term?See historical performance and comparison